Kewalramani Reshma's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Mar 3, 2026
- Accession no.
- 0000875320-26-000129
- Filed
- Mar 3, 2026
- Trade date
- Feb 27, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 13 non-derivative transactions and 0 derivative transactions. Open-market sales total $19.7M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kewalramani ReshmaCIK 0001735944 | Director, Officer (CEO & President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | SSaleDisposed | −400 | $479.75 | −$191,900 | 137,878 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −120 | $481.50 | −$57,780 | 137,758 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −240 | $482.84 | −$115,881.6 | 137,518 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −2,510 | $487.13 | −$1,222,696.3 | 135,008 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −3,278 | $488.27 | −$1,600,549.06 | 131,730 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −460 | $489.32 | −$225,087.2 | 131,270 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −2,725 | $490.54 | −$1,336,721.5 | 128,545 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −949 | $491.30 | −$466,243.7 | 127,596 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −2,520 | $493.29 | −$1,243,090.8 | 125,076 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −3,498 | $494.33 | −$1,729,166.34 | 121,578 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −15,580 | $495.38 | −$7,718,020.4 | 105,998 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −5,995 | $496.16 | −$2,974,479.2 | 100,003 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −1,725 | $496.95 | −$857,238.75 | 98,278 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.